Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 171

The DOI matches its Crossref record.

Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.

Tabernero, Josep, Van Cutsem, Eric, Bang, Yung-Jue, Fuchs, Charles S., Wyrwicz, Lucjan, Lee, Keun Wook, Kudaba, Iveta, Garrido, Marcelo, Chung, Hyun Cheol, Castro Salguero, Hugo Raul, Mansoor, Wasat, Braghiroli, Maria Ignez Freitas Melro, Goekkurt, Eray, Chao, Joseph, Wainberg, Zev A., Kher, Uma, Shah, Sukrut, Kang, SoonMo Peter, Shitara, Kohei · 2019 · Journal of Clinical Oncology

Abstract

LBA4007 Background: KEYNOTE062 (NCT02494583) was a randomized, active controlled study of 1L P or P+C vs C in pts with PD-L1 combined positive score ≥1 (CPS ≥1), HER2-negative, advanced GC. Methods: Eligible pts were randomized 1:1:1 to P 200 mg Q3W for up to 2 y, P+C (cisplatin 80 mg/m 2 + 5-FU 800 mg/m 2/d on d1-d5 Q3W [or capecitabine 1000 mg/m 2 BID on d1-d14 Q3W per local guideline]) or placebo Q3W + C. Randomization was stratified by region, disease status, and fluoropyrimidine treatment. Primary endpoints were OS in CPS ≥1 and CPS ≥10 for P+C vs C and P vs C and PFS (RECIST v1.1; central review) in CPS ≥1 for P+C vs C. ORR (RECIST v1.1; central review) in CPS ≥1 for P+C vs C was the secondary endpoint. Final analysis cutoff date was 26 Mar 2019. Results: 763 pts (281 with CPS ≥10) were randomized to P+C (257), P (256), or C (250) (Table). Median follow-up was 11.3 mo. P was noninferior to C for OS in CPS ≥1 per prespecified margins. P vs C prolonged OS in CPS ≥10 (median 17.4 vs 10.8 mo; HR 0.69; 95% CI 0.49-0.97) but wasn’t tested per analysis plan. P+C vs C was not superior for OS in CPS ≥1 or CPS ≥10, with a favorable trend for P+C. P+C did not significantly prolong PFS in CPS ≥1. ORR was higher for P+C vs C. Grade 3-5 drug-related AE rates were 17% (P), 73% (P+C), and 69% (C). Conclusions: As 1L therapy for advanced GC, P was noninferior to C for OS in CPS ≥1 with clinically meaningful improvement for OS in CPS ≥10. P+C did not show superior OS and PFS in CPS ≥1 and OS in CPS ≥10. The safety profile was more favorable for P vs C. Clinical trial information: NCT02494583. [Table: see text]

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2019.37.18_suppl.lba4007

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 171

Metadata

Authors
Tabernero, J., Van Cutsem, E., Bang, Y.-J., Fuchs, C. S., Wyrwicz, L., Lee, K. W., Kudaba, I., Garrido, M., Chung, H. C., Castro Salguero, H. R., Mansoor, W., Braghiroli, M. I. F. M., Goekkurt, E., Chao, J., Wainberg, Z. A., Kher, U., Shah, S., Kang, S. P., & Shitara, K.
Venue
Journal of Clinical Oncology
Published
2019-06-20
Volume
37
Issue
18_suppl
Pages
LBA4007-LBA4007
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2948169107
Cited by
171
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study. https://app.cochat.ai/papers/10.1200/jco.2019.37.18_suppl.lba4007
The paper
Tabernero, J., Van Cutsem, E., Bang, Y.-J., Fuchs, C. S., Wyrwicz, L., Lee, K. W., Kudaba, I., Garrido, M., Chung, H. C., Castro Salguero, H. R., Mansoor, W., Braghiroli, M. I. F. M., Goekkurt, E., Chao, J., Wainberg, Z. A., Kher, U., Shah, S., Kang, S. P., & Shitara, K. (2019). Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2019.37.18_suppl.lba4007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.